Metformin in PCOS: What It Helps, What It Doesn't, and Why It Matters

Polycystic ovary syndrome (PCOS) affects 10–13% of reproductive-aged women and carries a complex burden: hormonal dysregulation, metabolic disease risk (including a 4–7-fold elevated lifetime risk of type 2 diabetes), cardiovascular complications, infertility, dermatological symptoms, and significant psychological comorbidity. Managing PCOS across the reproductive lifespan—especially during pregnancy—requires carefully selected pharmacotherapy, as many standard agents (combined oral contraceptives, GLP-1 receptor agonists, anti-androgens, thiazolidinediones) are contraindicated in pregnancy. Metformin, a first-line insulin sensitizer with decades of use, has emerged as the most viable pharmacological option for many women with PCOS, yet its precise role remains debated.

This review, authored by researchers at Monash University and the Norwegian University of Science and Technology, synthesizes mechanisms of action and clinical outcomes across metabolic, hormonal, reproductive, and pregnancy domains. Mechanistically, metformin reduces hepatic gluconeogenesis, enhances peripheral glucose uptake, activates AMPK pathways, modulates gut microbiota, and may directly reduce ovarian androgen synthesis. It also reduces circulating insulin—a key driver of PCOS pathophysiology—without causing hypoglycemia or weight gain.

In non-pregnant women with PCOS, metformin consistently improves fasting insulin, HOMA-IR, and free androgen index, and modestly improves menstrual cycle regularity. These benefits are most pronounced in women with obesity or overt insulin resistance. However, metformin is not effective as monotherapy for weight loss, ovulation induction, or clinical hyperandrogenic features like hirsutism and acne. When combined with letrozole or clomiphene citrate for ovulation induction, metformin may improve ovulation and live birth rates. It also reduces the risk of ovarian hyperstimulation syndrome during assisted reproduction.

In pregnancy, metformin crosses the placenta, yet evidence supports its general safety for the fetus. Clinical trials and meta-analyses suggest metformin may reduce early pregnancy loss, preterm birth, and gestational weight gain in PCOS pregnancies. However, findings for gestational diabetes mellitus (GDM) and preeclampsia are mixed, with some trials showing benefit and others showing none. Of note, offspring exposed to metformin in utero may have slightly larger head circumference and elevated risk of overweight in early childhood, raising questions about long-term epigenetic or metabolic programming—though robust longitudinal data are lacking.

The review identifies several important caveats: meta-analyses rely largely on aggregate data from heterogeneous trials using varying PCOS diagnostic criteria, different metformin doses, and diverse clinical endpoints. Individual patient data meta-analyses and adequately powered, long-duration RCTs are needed to define which PCOS subpopulations benefit most and to clarify offspring outcomes. The authors also highlight that metformin is not a universal solution and should be deployed within a broader, individualized care framework that includes lifestyle modification, psychological support, and targeted pharmacotherapy.